We have previously identified a subgroup of pleomorphic salivary gland adenomas with ring chromosomes of uncertain derivation. Here, we have used spectral karyotyping (SKY), fluorescence in situ hybridization (FISH) and high-resolution oligonucleotide array-CGH to determine the origin and content of these rings and to identify genes disrupted as a result of ring formation. Of 16 tumors with rings, 11 were derived from chromosome 8, 3 from chromosome 5 and 1 each from chromosomes 1, 6 and 9. Array-CGH revealed that 10/11 r(8) consisted of amplification of a 19 Mb pericentromeric segment with recurrent breakpoints in FGFR1 in 8p12 and in PLAG1 in 8q12.1. Molecular analyses revealed that ring formation consistently generated novel FGFR1-PLAG1 gene fusions in which the 5 0 -part of FGFR1 is linked to the coding sequence of PLAG1. An alternative mechanism of PLAG1 activation was found in tumors with copy number gain of an intact PLAG1 gene. Rings derived from chromosomes 1, 5, 6 or 9 did not result in gene fusions, but rather resulted in losses indicative of the involvement of putative tumor suppressor genes on 8p, 5p, 5q and/or 6q. Our findings also reveal a novel mechanism by which FGFR1 contributes to oncogenesis and further illustrate the versatility of the FGFR1 and PLAG1 genes in tumorigenesis.
Introduction
The pleomorphic adenoma is the most common salivary gland tumor and accounts for about 60% of all salivary gland neoplasms (Eveson et al., 2005) . Pleomorphic adenomas most commonly occur in the parotid gland and less frequently in the submandibular and minor salivary glands. It is a benign tumor showing a remarkable degree of morphological diversity, including epithelial and myoepithelial cells forming a variety of patterns in an often mucoid/myxoid or condroid matrix. Pleomorphic adenomas may cause problems in the clinical management due to its tendency to recur and the risk of malignant transformation.
Extensive cytogenetic studies have shown that pleomorphic adenomas are frequently characterized by chromosome translocations with consistent breakpoints at chromosome bands 8q12 or 12q14-15 (Stenman, 2005) . We have previously identified the DNA-binding transcription factor genes PLAG1 and HMGA2 as the target genes of these translocations and shown that they result in fusion oncogenes (Schoenmakers et al., 1995; Geurts et al., 1997; Kas et al., 1997) . PLAG1 fusions are far more common than HMGA2 fusions and are found in at least 50% of karyotypically abnormal tumors (Stenman, 2005) . The breakpoints in PLAG1 occur in the 5 0 -noncoding part of the gene, leading to promoter swapping or substitution between PLAG1 and a fusion partner gene (Kas et al., 1997; Voz et al., 1998; Å stro¨m et al., 1999; Asp et al., 2006) PLAG1 fusions usually result in ectopic expression of a normal PLAG1 protein.
The PLAG1 protein contains an N-terminal zinc-finger DNA-binding domain and a C-terminal transactivation domain (Kas et al., 1997 . PLAG1 activates transcription through binding to a bipartite DNA-binding consensus sequence consisting of a core sequence (GRGGC) and a G-cluster (RGGK) . It has been suggested that PLAG1 exerts its major oncogenic effects by induction of growth factors such as insulin-like growth factor 2 (IGF2) (Voz et al., 2004) .
We have previously identified a subgroup of pleomorphic adenomas with ring chromosomes of uncertain origin (Mark et al., 1983; Stenman, 2005) . To determine the derivation and genetic content of these rings, we have now molecularly characterized 16 tumors with one or more ring chromosomes. Using spectral karyotyping (SKY), fluorescence in situ hybridization (FISH) and high-resolution oligonucleotide array-CGH (aCGH) analyses, we could show that in 11 tumors, the rings were derived from chromosome 8. Moreover, aCGH analysis revealed that 10 of the r(8) chromosomes consisted of amplification of a pericentromeric region of chromosome 8 with breakpoints in the FGFR1 gene in 8p12 and in the PLAG1 gene in 8q12. Reverse transcriptase PCR (RT-PCR) analysis confirmed that the r(8) in all cases resulted in a novel FGFR1-PLAG1 gene fusion. Our results reveal a new mechanism of formation of gene fusions and subsequent amplification in ring chromosomes in epithelial tumors.
Results

Cytogenetic and SKY analyses
The karyotypic findings based on G-banding, SKY and aCGH are summarized in Table 1 and Figure 1a . All tumors had pseudodiploid or hyperdiploid karyotypes with clonal structural aberrations. Sixteen tumors had one or more ring chromosomes and one tumor had trisomy 8 as the sole anomaly. SKY analysis revealed the derivation of all ring chromosomes and markers and showed that each ring only contained material from a single chromosome (Figure 1a ). Eleven tumors had rings derived from chromosome 8 and three had rings derived from chromosome 5, one of which also had an r(1). The two remaining tumors had rings derived from chromosomes 6 and 9, respectively. Two tumors had supernumerary r(8) and four tumors contained 2-4 copies of the r(8).
aCGH and FISH analyses of tumors with r(8) reveal consistent copy number gains of 8p12-q12.1 To fine map the breakpoints and determine the genetic content of the rings, we performed aCGH analysis of 14 tumors. A detailed description of all gains and losses recorded are given in Table 1 . In general, losses were four times more common than gains. However, the most prominent finding was a consistent copy number gain of the pericentromeric segment 8p12Àq12.1 in eight tumors with r(8). Other recurrent copy number alterations were losses of one or more regions within 3p21.3 and 7q11.21-q11.23 in six and four tumors, respectively, 8p12-pter in three tumors and 5p14.1-pter and 5q21.1-qter in two tumors. There were also four cases with loss of partly overlapping segments of 6q.
Analyses of the 44K arrays revealed consistent breakpoints within or close to the FGFR1 gene in 8p12 and close to the PLAG1 gene in 8q12 in tumors with r(8). To refine the mapping of these breakpoints, we analyzed four tumors with high-resolution 244K arrays. Detailed analysis of these arrays unequivocally demonstrated that the breakpoints had occurred within the 5 0 -parts of the FGFR1 and PLAG1 genes in all four tumors (Figure 2a) , suggesting a possible fusion between these two genes as a result of the formation of r(8). In three of the 11 tumors with r(8), there was a concomitant loss of the segment distal to 8p12. In cases 3, 6 and 8, the 8p12-pter segment was translocated onto 6q14.1, 10q22.1 and 6q22.1, respectively. In none of these cases, aCGH indicated that the translocations had resulted in a fusion between the 3 0 -part of FGFR1 (including the tyrosine kinase domain) and a putative 5 0 -fusion partner on 6q or 10q.
aCGH analysis of the r(8) in case 11 revealed copy number gain of the 8q10Àq21.11 segment including PLAG1 (Table 1; Figure 2b ). The proximal breakpoint was in the centromere and the distal breakpoint within or immediately distal to the CRISPLD1 gene. Similarly, aCGH analysis of case 12 revealed gain of one copy of chromosome 8, including an intact PLAG1 gene.
aCGH analysis of two of the three tumors with r(5) revealed similar, but not identical, breakpoints in 5p14.1 and 5q21.1 with concomitant losses of the segments distal to these breakpoints (Figure 2c ). In case 13, the 5p14.1 breakpoint was between the CDH9 and CDH6 genes, and in case 14, it was between CDH9 and CDH10. The corresponding breakpoints in 5q21.1 were between SLCO4C1 and SLCO6A1, and SLCO6A1 and PAM, respectively. The third case with r(5) had slightly different breakpoints located in 5p11 and 5q22 (Table 1) .
Of the remaining two cases with ring chromosomes, that is, r(6) in case 16 and r(9) in case 17, only the 6p14.1 breakpoint in the r(6) was associated with a copy number alteration, allowing a more detailed mapping by aCGH. This breakpoint was located between the IMPG1 and HTR1B genes.
The variable size of the r(8) both within individual tumors and between tumors prompted us to study the copy number of PLAG1 in r(8) from seven tumors. FISH analyses using PLAG1-specific probes and a CEP8 probe revealed multiple dual signals on all r(8) as well as in micronuclei from several cases (Figures 1b  and c) . The number of PLAG1 and CEP8 signals in each r(8) varied from two to eight (Table 1 ). The sizes of the rings correlated well with the number of PLAG1 and CEP8 signals. However, FISH analysis revealed a higher copy number of PLAG1 than aCGH did. This difference may be explained by in vitro selection of cells with high copy number gain of PLAG1, intratumor heterogeneity and/or by the fact that most aCGH-platforms quantitatively underestimate copy number changes in log2 ratios (Pollack et al., 1999; Brennan et al., 2004) .
FISH analysis of case 12, which had trisomy 8 as the sole anomaly, revealed three copies of PLAG1. Rings derived from chromosomes other than 8, that is r(1), r(5), r(6) and r(9), were consistently negative for PLAG1 sequences. Case 15, which had a t(3;8) as well as r(1) and r(5), showed a split signal for YAC 166F4, consistent with a CTNNB1-PLAG1 gene fusion. Approximate sizes in megabases of gained and lost segments are shown in square brackets.
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of FGFR1 to the 3 0 -part of PLAG1. Using primers located in exon 1 of FGFR1 and in exon 4 of PLAG1, we could show that 9 of the 10 cases with r(8) expressed FGFR1-PLAG1 fusion transcripts (Figure 3a) . aCGH analysis of the 10th case revealed identical breakpoints in FGFR1 and PLAG1, strongly indicating that this case also has an FGFR1-PLAG1 gene fusion.
Four different types of FGFR1-PLAG1 fusion transcripts were detected (Figure 3a) . Nucleotide sequence analysis showed that seven tumors expressed chimeric transcripts containing exon 1 of FGFR1 fused to either exon 2 or 3 of PLAG1 and two tumors expressed chimeric transcripts consisting of exon 2 of FGFR1 fused to either exons 2 or 3 of PLAG1 (GenBank accession numbers EF525168, EF525169, EF525170 and EF525171). The breakpoint in FGFR1 in the latter two cases was in intron 2, resulting in a fusion of 5 0 -noncoding sequences as well as 91 nucleotides of the coding region to the acceptor splice site of PLAG1 exon 2 or 3. 
FGFR1-PLAG1 gene fusion and amplification F Persson et al
As expected, case 11 with an r(8)(q10q21.11) as well as the cases with trisomy 8, r(5), r(6) and r(9) were all negative for the FGFR1-PLAG1 fusion (Figure 3a) . Cases 11 and 12 were also analyzed for expression of two recently described cryptic PLAG1 gene fusions, CHCHD7-PLAG1 and TCEA1-PLAG1 (Asp et al., 2006) . In addition, case 4, which had a der(3)t(3;8), was analyzed for expression of the CTNNB1-PLAG1 fusion. RT-PCR analyses revealed that none of these tumors expressed any of these fusion transcripts (data not shown).
Overexpression of PLAG1 in tumors with fusion and amplification of the FGFR1 and PLAG1 genes To study the consequences of fusion and amplification of the FGFR1 and PLAG1 genes on PLAG1 expression, we performed real-time quantitative PCR on 10 of the 12 tumors with r(8) or trisomy 8. All tumors overexpressed PLAG1 relative to normal salivary gland tissue (Figure 3b ). In general, the expression levels were equal or higher in tumors with r(8) and FGFR1-PLAG1 fusions compared to tumors with CTNNB1-PLAG1 fusions. The tumor with the highest expression level of PLAG1 had also the highest number of PLAG1 copies per r(8) (case 3). Case 12, which was trisomic for chromosome 8, expressed similar levels of PLAG1 as the cases with CTNNB1-PLAG1 fusions.
We also evaluated the expression of the PLAG1 protein by immunohistochemistry in five tumors (cases 1-5) with r(8), resulting in fusion and copy number gain of FGFR1 and PLAG1. All tumors overexpressed the PLAG1 protein in the majority of cells and cell types. The staining was mainly nuclear. In line with the realtime PCR results, the highest expression level was noted in case 3 (Figure 3d) .
To study the impact of copy number gain of 8p12-q12.1 on other genes located within this segment, we also analyzed the expression of FGFR1 as well as of C8orf4 (TC1;8p11.21), MYST3 (8p11.21), DKK4 (8p11.21-p11.1), MCM4 (8q11.21) and SNAI2 (8q11.21) using real-time quantitative PCR. As expected, case 12, which was trisomic for chromosome 8, showed the highest expression level of FGFR1 (Figure 3c ). In the remaining tumors, there were no substantial differences in FGFR1 expression between tumors with r(8)/copy number gain and tumors with CTNNB1-PLAG1 gene fusions. Similar results were also obtained for C8orf4 (TC1), MYST3, DKK4, MCM4 and SNAI2 (data not shown).
Discussion
Here, we have used a combination of SKY, FISH and oligonucleotide aCGH to determine the origin and 
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F Persson et al genomic content of ring chromosomes in pleomorphic adenomas and to identify possible genes disrupted as a result of ring formation. Of the 16 tumors with one or more rings, 11 were derived from chromosome 8, three from chromosome 5 and one each from chromosomes 1, 6 and 9. High-resolution aCGH analysis using 44K arrays as well as the most recently released 244K oligonucleotide arrays revealed that the chromosome 8 rings in all but one case consisted of amplification of a pericentromeric segment with consistent breakpoints in the FGFR1 gene in 8p12 and in the PLAG1 gene in 8q12.1. RT-PCR and nucleotide sequence analyses confirmed that all 10 cases with r(8)(p12q12.1) had a novel FGFR1-PLAG1 gene fusion. All fusion-positive tumors expressed two alternatively spliced fusion transcripts. The majority of tumors (78%) expressed transcripts consisting of exon 1 of FGFR1 fused either exon 2 or 3 of PLAG1, and a few tumors (22%) expressed transcripts consisting of exon 2 of FGFR1 fused to either exon 2 or 3 of PLAG1. These transcript variants are consistent with breakpoints located in intron 1 of PLAG1 and in intron 1 or more rarely in intron 2 of FGFR1. Chimeric transcripts including exon 2 of FGFR1 and exons 2 or 3 of PLAG1 are predicted to encode truncated FGFR1-PLAG1 fusion proteins of 52 and 55 aminoacids, respectively, as well as a full-length PLAG1 protein. Whether these truncated fusion proteins, which do not contain functional FGFR1 tyrosine kinase domains, are biologically active, however, remains to be shown. Since the breakpoints in FGFR1 and PLAG1 occurred in the 5 0 -noncoding regions of both genes, the major molecular consequence of this fusion is likely to be activation of PLAG1 expression due to promoter substitution. Real-time quantitative PCR analysis confirmed that all FGFR1-PLAG1 positive tumors overexpressed PLAG1 relative to normal salivary gland tissue and that the expression levels were equal or higher in tumors with FGFR1-PLAG1 fusions and amplification compared to tumors with CTNNB1-PLAG1 fusions. The tumor with the highest number of PLAG1 copies per r(8) also expressed the highest level of PLAG1. The fact that there were no significant differences in expression levels of six other cancerassociated genes in 8p12-q12.1, including FGFR1, in tumors with r(8) or copy number gain of PLAG1 compared to tumors with CTNNB1-PLAG1 fusions 
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further emphasizes the critical role of PLAG1 in these tumors. However, we cannot exclude the possibility that other genes within 8p12-q12.1 could have oncogenic effects.
The r(8) chromosomes demonstrated considerable inter-and intratumor heterogeneity in both number and size. The number of rings per cell varied between one and four, and the number of PLAG1 copies per ring varied between two and eight. This variation may be caused by continuous rearrangement of the rings through breakage-fusion-bridge cycles as previously demonstrated for other types of low-and high-grade malignant tumors (Gisselsson et al., 1999 (Gisselsson et al., , 2000 .
Of the 11 tumors with r(8), one was negative for the FGFR1-PLAG1 fusion. aCGH and FISH analyses revealed that case 11 instead had a copy number gain of 8q10-q21.11 with at least two copies of PLAG1 per ring. This case is therefore equivalent to case 12, which was trisomic for chromosome 8 and PLAG1. The fact that both tumors overexpressed PLAG1 at similar levels as tumors with PLAG1-fusions demonstrates that copy number gain of an apparently normal PLAG1 gene is an alternative mechanism for activation of this gene.
Copy number gains or amplifications of gene fusions are very rare and have previously been observed only in a few types of neoplasms, including chronic myeloid leukemia with BCR-ABL fusions (Gorre et al., 2001; Johansson et al., 2002) . T-cell acute lymphoblastic leukemia with NUP214-ABL1 fusions (Graux et al., 2004) and dermatofibrosarcoma protuberans with COL1A1-PDGFB fusions (Abbott et al., 2006) . Interestingly, these studies have suggested that amplification of fusion genes may indicate progression towards a more malignant phenotype and an aggressive clinical course. Whether this holds true also for pleomorphic adenomas with genomic instability and FGFR1-PLAG1 gene fusions and/or copy number gain of PLAG1 remains to be shown.
Our findings of FGFR1-PLAG1 gene fusions and subsequent amplification in ring chromosomes reveal a novel mechanism by which FGFR1 contributes to tumorigenesis. FGFR1, which belongs to a family of four receptor tyrosine kinases, is a 92 kDa transmembrane protein with an extracellular domain containing three immunoglobulin-like C2-type domains, a heparin-binding site, a transmembrane domain and an intracellular thyrosine kinase domain (Eswarakumar et al., 2005) . FGFR1 is expressed in most tissues including normal fetal and adult salivary gland tissue (Hughes, 1997; Hoffman et al., 2002) . Interestingly, FGFR1 is also involved in the development of salivary glands by regulation of branching morphogenesis (Hoffman et al., 2002) .
Previous studies have clearly implicated FGFR1 in the pathogenesis of a variety of neoplasms. For example, in the 8p11 myeloproliferative syndrome (EMS)/stem cell leukemia-lymphoma syndrome, gene fusions are found in which various 5 0 -partners are fused to the tyrosine kinase encoded domain of the FGFR1 gene as a result of chromosomal translocations (Xiao et al., 1998; Roumiantsev et al., 2004) . The fusion proteins induce constitutive tyrosine kinase activation of FGFR1 by oligomerization. The FGFR1 fusions in EMS are clearly different from the FGFR1-PLAG1 fusions described here, in which the 5 0 -part of FGFR1, excluding the tyrosine kinase domain, are fused to the entire coding sequence of PLAG1. Moreover, previous studies have shown that amplifications of 8p11-12, including the FGFR1 gene, are found in several tumor types, including for instance breast (Ugolini et al., 1999; Reis-Filho et al., 2006) and colorectal carcinomas (Nakao et al., 2004) . Amplifications of the 8p11-12 region are often accompanied by loss of distal 8p, suggesting that one or more tumor suppressor genes are located on 8p (Pole et al., 2006) . In three of our tumors with fusion and amplification, there was also a concomitant loss of 8p12-pter. Whether these losses affect the same gene(s) as in breast and colorectal carcinomas remains to be shown.
Spectral karyotyping and aCGH analyses revealed that two tumors with r(5) had similar but not identical breakpoints in 5p14.1 and 5q21.1. The ring formation in these cases, however, did not result in any gain of chromosome 5 material. Nor did the breakpoints indicate that the formation of the rings could have resulted in gene fusions. Similarly, aCGH analysis of the breakpoints in the r(6) and r(9) did not indicate that gene fusions might have been generated as a result of the formation of these rings. Rather, our findings suggest that the rings could result in loss of one or more putative tumor suppressor genes located distal to the breakpoints on the short and long arms of chromosomes 5, 6 and 9.
Interestingly, six of the present tumors with ring chromosomes also showed submicroscopic deletions of one or more regions within 3p21.3. Malignancy-related deletions involving this region have previously been found not only in the majority of epithelial cancers but also in many lymphoid malignancies (Kok et al., 1997; Kost-Alimova et al., 2003; Kost-Alimova and Imreh, 2007) . Extensive experimental and clinical data suggest that this region harbors one or more tumor suppressor genes that when lost contribute to a malignant phenotype (Kost-Alimova et al., 2003; Kost-Alimova and Imreh, 2007) . It is therefore tempting to speculate that deletions within 3p21.3 could be an important genetic event that contributes to malignant transformation of pleomorphic adenomas.
Materials and methods
Tumor material
Fresh samples from 17 primary pleomorphic adenomas of the parotid gland were obtained from the Central Hospital, Sko¨vde, Sweden. Histopathological re-examination of the tumors confirmed the diagnosis of pleomorphic adenoma in all cases. The clinical-pathological characteristics of the tumors are shown in Table 1 . The tumors from eight patients (cases 3-6, 10, 11, 14 and 15) have not been reported previously. In the remaining nine tumors, the cytogenetic findings based on G-banding alone have been reported (Mark et al., 1988 (Mark et al., , 1997 .
For real-time PCR analysis, we used fresh frozen tumor tissue from four additional pleomorphic adenomas with Cytogenetic, spectral karyotype and fluoresence in situ hybridization analyses Primary cultures were established from fresh, unfixed tumor specimens (Nordkvist et al., 1994) . Chromosome preparations were made from primary cultures or early passage cells, and these were subsequently G-banded and analysed using standard procedures. Spectral karyotyping analysis was performed on 13 tumors (cases 1-6, 10, 11 and 13-17) using the SkyPaint probe kit (ASI-Applied Spectral Imaging Ltd, Migdal Ha'Emek, Israel) as described previously (Sjo¨gren et al., 2000) .
Fluoresence in situ hybridization analysis was performed on metaphase chromosomes from eight cases using the following PLAG1-specific probes: CEPH YAC 166F4, PAC233, PAC234 and PAC235 (Kas et al., 1997; Ro¨ijer et al., 2002) . Fluorescence signals were digitalized, processed and analyzed using the CytoVision image analysis system (Applied Imaging International Ltd, Newcastle-Upon-Tyne, UK). The number of PLAG1 and CEP8 signals were evaluated in at least 25 metaphases from each of the eight tumors.
Array-CGH analysis
Genomic DNA was isolated from frozen tumor tissue using the QIAamp R DNA Mini Kit (Qiagen GmbH, Hilden, Germany). aCGH analysis was performed using high-resolution 44K and 244K 60-mer oligonucleotide CGH-arrays containing approximately 43 000 and 236 000 probes, respectively (arrays G4410B and G4411B sourced from the National Center for Biotechnology Information (NCBI) genome Build 35; Agilent Technologies Inc., Palo Alto, CA, USA). These arrays have an average spatial resolution of about 35 and 6.4 kb, respectively. The aCGH experiments performed according to the recommendations of the manufacturer (Barrett et al., 2004) . Briefly, 3 mg each of tumor DNA and sex-matched reference DNA (Promega p/n G1471) were digested with AluI and Rsa1 for 2 h at 37 1C. Digested tumor and reference DNAs (1.5 mg of each) were labeled with Cy3-dUTP and Cy5-dUTP (Perkin-Elmer Life and Analytical Sciences Inc., Wellesley, MA, USA), respectively, and were thereafter pooled and mixed with human Cot-1 DNA in hybridization buffer (Agilent Oligo aCGH Hybridization Kit; Agilent Technologies), denatured and hybridized to the arrays. The hybridizations were carried out in hybridization chambers, placed in a rotating oven, at 65 1C for 40 h. The arrays were subsequently washed, dried and scanned using a G2505B Agilent DNA microarray scanner (Agilent Technologies). Microarray images were analyzed using Feature Extraction v.9.1 (Agilent Technologies) with linear normalization (protocol CGH-v4_91), and the data were subsequently imported into the CGH Analytics software v.3.4.27 (Agilent Technologies). Detection of gains and losses were based on (i) the z-score algorithm (threshold 2.5) with a moving average of 500 kb and (ii) visual inspection of the log2 ratios. In general, log2 ratios X0.4 in at least five consecutive probes were considered as a reliable copy number alteration.
RT-PCR and nucleotide sequence analyses Total RNA was extracted from frozen tumor tissue using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA). DNasetreated (DNA-free; Ambion, Austin, TX, USA) total RNA was subsequently converted to cDNA using the SuperScript First-Strand Synthesis System (Invitrogen). As a control for intact RNA and cDNA, RT-PCR reactions for expression of GAPDH were performed on all cDNAs (Asp et al., 2006) . The FGFR1-PLAG1 fusion transcript was amplified by PCR using the primers FGFR1-602F-5 0 -TCGCACAAGCCACG GCGG3 0 (exon 1 of FGFR1) and PLAG1-445AS-5 0 -GGAA CTGCCCAACTCCACTA-3 0 (exon 4 of PLAG1). PCR amplification of the CHCHD7-PLAG1 and TCEA1-PLAG1 fusion transcripts were performed as described previously (Asp et al., 2006) . PCR products were gel-purified and sequenced using an ABI PRISM 310 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). The resulting sequences were analyzed using the BLAST-tool provided by the NCBI (http://www.ncbi.nlm.nih.gov).
Quantitative real-time PCR analysis
Quantitative real-time PCR analysis was performed using the AB 7500 Fast Real-Time PCR system (Applied Biosystems). The following genes were analysed using TaqMan Gene Expression assays; PLAG1 (Hs00965048_m1), FGFR1 (Hs00241111_m1), DKK4 (Hs00205290_m1), MCM4 (Hs00381533_m1), MYST3 (Hs00198899_m1), SNAI2 (Hs00161904_m1) and C8orf4 (Hs00535539_s1) (Applied Biosystems). All samples were assayed in triplicates. To enable detection of possible contaminating genomic DNA, we analysed non-reversed transcribed total RNA in parallel with the cDNAs. The relative expression levels of all genes were calculated using the comparative C t method (DDC t ) and the SDS Software v1.3.1 (Applied Biosystems) using GAPDH (Hs99999905_m1) as endogenous control and cDNA from normal salivary gland tissue as calibrator (Livak and Schmittgen, 2001 ).
Immunohistochemistry
For immunohistochemistry, tissue sections were treated as previously described and incubated overnight at 4 1C with a PLAG1 polyclonal antibody (diluted 1:200) raised against a peptide in the N-terminal part of the protein (Asp et al., 2006) . Bound antibodies were visualized using the indirect immunoperoxidase technique DAKO EnVision þ System (DakoCytomation, Glostrup, Denmark). Control sections were incubated identically, except for the primary antibody, which was replaced by normal rabbit serum/mouse IgG.
